Back to School: How biopharma can reboot drug development. Access exclusive analysis here
UCB Group (Euronext:UCB) granted R-Pharm CJSC (Moscow, Russia) exclusive, worldwide rights to develop and commercialize olokizumab, a
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury